iBio (IBIO) Stock Forecast & Price Target

iBio is supported by a differentiated platform that has produced four ligand-selective antibodies across obesity, cardiometabolic, and cardiopulmonary disease, with IBIO-610 standing out because human genetics, preclinical potency, and NHP suppression of Activin E up to 98% all converge on the same target biology. The investment case is strengthened by commercial optionality: IBIO-610 showed semaglutide-compatible fat loss with reduced lean-mass loss, IBIO-600 entered Phase 1 in June 2026, and the bispecific program is indirectly validated by GSK’s roughly $950 million HS235 acquisition. Financially, the company held about $88.0 million of cash and investments as of June 30, 2026, with runway extending into 2028, while current valuation appears to understate a pipeline that spans obesity maintenance, rare muscle disease, and pulmonary hypertension.

iBio is fundamentally weakened by a pre-revenue, development-stage profile with no marketed products, persistent operating losses since inception, and an ongoing need to raise debt or equity that could dilute shareholders or come on restrictive terms. Its pipeline also faces substantial scientific and clinical risk, as activin-pathway and myostatin biology have shown limited human translation and meaningful safety concerns, including pericardial effusions, higher serious adverse events, and discontinuations in related programs. On top of that, the company must still build sales and manufacturing infrastructure while facing intense competition, uncertain IP protection, and explicit regulatory risk for IBIO-610 and IBIO-600 in the US and EU.